Ikena Oncology to merge with Inmagene Biopharmaceuticals.

Ikena Oncology, a targeted oncology company, to merge with Inmagene Biopharmaceuticals, a global clinical-stage biotechnology company. Financial terms were not disclosed. “In our search for the right partner for Ikena, Inmagene’s IMG-007 differentiated clinical data in atopic dermatitis and potential as a pipeline in a product across the I&I space was a compelling fit,” Mark Manfredi, Ikena CEO.